{"name":"Effector Therapeutics","slug":"effector-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9uSDlYWEpJYXdhQ2drQzhYOHJLd0twQ2Y1WE9rdGlISEk2ZngwWG9ETDNGMHpKQ2Utb0tVcGFNTGVvdEt6VjN1aWE0YWlMaThtd3l2TVdYQ3Z0cEw1RDJFZHlkZnU2WEZUMTdJdGd3ZHFzNUk?oc=5","date":"2025-10-15","type":"trial","source":"Taylor & Francis Online","summary":"HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors: Future Oncology: Vol 21, No 25 - Taylor & Francis Online","headline":"HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors: F","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFBScXRtQ0tnTHAtQ1RNeTQwUm9HcmNXWXVJUzg0NGo4b2dUVnVYSS01ekpBUlpXa1J0bDlpWlhham5ubzhYZXh4dW5yanlVR19ZSnc?oc=5","date":"2025-06-06","type":"trial","source":"Endpoints News","summary":"IPO Tracker (2021) - Endpoints News","headline":"IPO Tracker (2021)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE0tM0xwcWxadjY0NDJVZm5VZHpGTmNqMWtScDVjSVJQLVBxeE02SGNIdDUxdWp1WG9ncUVyVGQ5ZVJGaU9lZHJMcnl2RFFMajlTbENyUWlUazFrUWhsNDVFNkNmbDJKTlU?oc=5","date":"2025-05-31","type":"pipeline","source":"MedPage Today","summary":"First-Line Keytruda-Trodelvy Boosts PFS in Triple-Negative Breast Cancer - MedPage Today","headline":"First-Line Keytruda-Trodelvy Boosts PFS in Triple-Negative Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxONlZtNEx2dnA2c2pwUGY5Zm8tWHR6TVF1RWVxMlJwUkplSFYtVmNCQl8xZXlvVDRldTRqSVY4UjZKUTh1RUlwVjExVkFxMkttakZNNjZCQ05meEpfTlpyTTVrM3BQZWdYQkR4VDVxd2ZkVWhjUVJmbmNLSFJPSGRrQXM1WkNhNlhqblRDcjZ3?oc=5","date":"2025-03-03","type":"trial","source":"Oncology Pipeline","summary":"Hello BridgeBio, farewell Syros and Achilles | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Hello BridgeBio, farewell Syros and Achilles | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNV0FCOWlaWkUzRTBWdmJmUGZjbVB1UzlFMTJXSUFzcnF4UmhjeGZPZk1oZlQwRWNkamsyaXZtWkkzNW5GWlNTem5ETGtxTnV1RVRpT2lRSWdQYVBjM0h4bzlPbmFLWV91dTNDdWR4X1huaVJpUjdSeXI1RnJ3NVZ6QzNTZFFRUFRDeEZhZjQ5VWpfdw?oc=5","date":"2024-06-25","type":"pipeline","source":"sfgate.com","summary":"Calif. biotech company that raised $325 million shuts down, lays off all workers - sfgate.com","headline":"Calif. biotech company that raised $325 million shuts down, lays off all workers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNdm94ZFlLZ1o2WXRzUXRDTmw3Umxmb0I1OXhpcUdqMjVOcjVnbTJ5aXdjQXBRQTlVXzNiU2NldE9FY1ptSmF5b0NyeXVCMXFsSDlUdng1M2NkN1JMNHVIZVNPYzlHcjVkRDZIWDdFTzhnSmhFbjZab1NEYWdSY3BzdTROTnZhVENzOGEyRnBvaUpfUzJBWHBpb1dDY2hFTEhtREZZME1TQ2t4b2Y5MFk4dHJn?oc=5","date":"2024-06-24","type":"pipeline","source":"Fierce Biotech","summary":"The end of eFFECTOR Therapeutics: Oncology biotech winds down after midstage fail - Fierce Biotech","headline":"The end of eFFECTOR Therapeutics: Oncology biotech winds down after midstage fail","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSjVsOWNOWmpUSk1TcXZPbThfYXdmUV9VZGp6QXRiSkcxREZMaGg0bTA1YUNERnZodVItNE9zUUxjc0MzQk1RYUJ3MkRYN0FfanJBYmQyZ0JaQVppSzlMUGhUaU83RjVGb21fbU5ycVBGR3BHZ3BzanlNdnJ4OXphbjhZYWNZd1hGN1ZoT2ROV3lxbzdiYmtEbnJtMERqTzd1eVVWTlFfZm9qckE?oc=5","date":"2024-04-04","type":"trial","source":"Clinical Trials Arena","summary":"eFFECTOR shelves tomivosertib in NSCLC following Phase II failure - Clinical Trials Arena","headline":"eFFECTOR shelves tomivosertib in NSCLC following Phase II failure","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPTU9tdDFTcGltR2Z3SXF2cnBycEpQNmU4OXB5MndId012UWVIVVhKTWVLQXhNbnNDb3FhMWt4Ql9ad29DeU41NmdqM05oTnZybEVncWVObDBlcEVXbVc0bU8tckhmYUp6TXFYdWtEY0tDamJsTzREMmM2MmxmMm10M080bXRvX3J0OWRfa1c2T1ZGZGhsR0ppSDE3M2FBOVd1THZCQmhKNjl2V0k4UHRZ?oc=5","date":"2023-12-01","type":"regulatory","source":"Pharmaceutical Executive","summary":"FDA Fast Tracks eFFECTOR Therapeutics' Zotatifin Combo for ER+/HER2– Breast Cancer - Pharmaceutical Executive","headline":"FDA Fast Tracks eFFECTOR Therapeutics' Zotatifin Combo for ER+/HER2– Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTE5QNmI1UUNCSWE0Ym92Rl9xSU90R3F6d04xbEdhT1ZaNFpNNVBFT2tBN3VxZTBNNkhMclhkbFA2M0FvTUNJLU5yOVV6TVkyZw?oc=5","date":"2021-08-25","type":"pipeline","source":"Stock Titan","summary":"Latest EFTR News - eFFECTOR Therapeutics Announces it will Win... - Stock Titan","headline":"Latest EFTR News - eFFECTOR Therapeutics Announces it will Win...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNLUVLUVRVbzdNTXpBalFkRlJWa0pSYmJrQWhQTFU2ZjhSMXd0QThlY3hZQmVTUFFpbW9PX2plOU9lV3pRZTg5YlVhOVhuQlFTc2ZSWjlkNklqSHg0eUtLYWt1N1ExLTZHVXoxemVvNkRkSVhLYno0QmRUeDllWmlBRVZHUV9ybjVlajRnZk80VkZWcWlIenBBQ3hiZlJPRmdpMVcwSWdWQ3I2d0JJZ0hjeDZOZVNaSGdu?oc=5","date":"2021-05-27","type":"pipeline","source":"Fierce Biotech","summary":"EFFECTOR Therapeutics bugs out of an IPO, taking the SPAC path with Locust Walk - Fierce Biotech","headline":"EFFECTOR Therapeutics bugs out of an IPO, taking the SPAC path with Locust Walk","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxONVJOVzNjNGJrRWwtNGlZZHJEdjJJNWN2R1JVeThZVXdLcThXZHppc2ZCWXpnMVZtelU2bVNJYUhaRzI3eWN5bm42TEQzMm0zdVEwdnNPWVpDZVM2S21HMDgzS1Z3QWVXZF9fZEdCbVhNRkxmcUMyVm1Xa0s5SmoybEVfSVpXUQ?oc=5","date":"2020-01-09","type":"pipeline","source":"C&EN","summary":"Pfizer taps Effector Therapeutics for its anticancer translation inhibitor - C&EN","headline":"Pfizer taps Effector Therapeutics for its anticancer translation inhibitor - C&EN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQbGZEWl9vTzN6UFBlLV9fOWt0WGdtMlloMWhEZG9IM3ljUWh3VmgwSW1QRGpQRVl2aVJycVhRbU5ST3Q2bVlud2tMNTQteVllZHBXN1ZnX0gyZ0lKUEhXWXJ1djBUc1pULUoxcV9qUkJyalhzblZSWWpiNlFQMmVmSmdZcFJRVzE4aTJpclBFbVBiM19YeGJXNmZnTDZNT21yNnNLQkpyUkpqd0FWdk5kZV9HWlVTdVRl?oc=5","date":"2013-05-20","type":"pipeline","source":"PR Newswire","summary":"eFFECTOR Therapeutics Raises $45 Million in Series A Financing - PR Newswire","headline":"eFFECTOR Therapeutics Raises $45 Million in Series A Financing","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}